AKYA - Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share Prices
2024-02-12 22:49:38 ET
Summary
- Liquidia's stock has increased in value by 209.32% since June 2022.
- Liquidia's PAH drug, Yutrepia, is expected to launch in the first or second quarter of 2024, potentially leading to profitability.
- Liquidia has gained a major partnership for a sustained-release inhaled Treprostinil product, which could compete with United Therapeutics' revenue products.
On June 29, 2022, I had an SA article titled Liquidia ( LQDA ) vs. MannKind ( MNKD ): Treprostinil Is the Big ‘IF .’ At the end of the article, I indicated to the readers that my choice in the contest as to who would dominate the market with their respective PAH drug, the winner would be Liquidia.
Eighteen months later, Liquidia’s stock has increased by more than 200%. This dramatic increase in their share price has changed my short-term thesis for the stock. However, my long-term thesis remains in place. But any prudent investor should take advantage of their ownership in a stock that has more than doubled if they have identified another stock that might offer the same growth potential in the near term. What I have done with my portfolio is sell a little more than 50% of my Liquidia's position. It should be noted that with the shares I accumulated over a long term, the shares I kept are up more than 100%....
Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share Prices